This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Impotence Drugs Keep Golf Going

Men and women of the links consider themselves the most vigorous of people. That's why it has been a struggle for golfers to embrace erectile-dysfunction sponsorships.

To watch tournaments on TV is to be bombarded with the notion that impotence is widespread among golfers. Where does this perception come from? Demographics, surely. The bean counters at the drug companies must look at golf's actuarial tables and think, "This is the sweet spot."

And thank heavens for that.

Golf Courses

Can you imagine what would happen if pharmaceutical companies stopped using golf to promote Eli Lilly's (LLY - Get Report) Cialis, Bayer's (BAYRY) Levitra and Pfizer's (PFE - Get Report) Viagra? It could mark the end of televised golf. With other sponsors scaling back, erectile dysfunction drugs have helped keep the sport on the air.

Consider the PGA Tour's tournament partners:

Banks: Many are bankrupt, going bankrupt or being scooped up by competitors. U.S. Bancorp (USB) isn't renewing its sponsorship deal in Milwaukee. What do Friedman, Billings, Ramsey (FBR); Northern Trust (NTRS); Banco Popular; Wachovia (WFC); Morgan Stanley (MS); Barclays (BCS); and Deutsche Bank (DB) have in common? They all sponsor PGA Tour events -- for now.

Real estate: If you believe the housing market is headed for a quick recovery, I have a great home to sell you, with views of the 12th hole at Augusta National. Ginn Resorts foreclosed on its deals with the PGA and LPGA tours, and with professional golfer Cristie Kerr.

Automotive: I haven't run the numbers, but I'm pretty sure Tiger Woods' net worth now exceeds that of former endorsement partner Buick. Sponsors Mercedes-Benz (DAI), BMW and Honda (HMC) have all hit the skids recently.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
BAYRY $144.60 0.00%
LLY $72.47 0.00%
PFE $35.04 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs